Brief: Ose Immunotherapeutics Announces Article Publication On OSE-230 Therapy
19/07/2023 18:10
July 19 (Reuters) - OSE Immunotherapeutics SA OSE.PA :
* OSE IMMUNOTHERAPEUTICS ANNOUNCES PUBLICATION IN FRONTIERS
IN
IMMUNOLOGY ON OSE-230, ITS NOVEL AGONIST THERAPY IN CHRONIC
INFLAMMATION
* RESEARCH DEMONSTRATED REPROGRAMMING OF TAM THROUGH
ACTIVATION OF
CHEMR23 BY OSE-230
Source text for Eikon: ID:nBw4dMdvva
Further company coverage: OSE.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48587696600;))
Recent news on Ose Immunotherapeutics SA
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Brief: OSE Immunotherapeutics SA Appoints Thomas Gidoin As Deputy CEO
Brief: Ose Immunotherapeutics Will Pause Development Of OSE‑230
Brief: OSE Immunotherapeutics Gets Second Positive IDMC Nod For Phase 3 Lung Cancer Trial
Brief: OSE Immunotherapeutics Announces Appointment Of Marc Le Bozec As Interim CEO